We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-5.68%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.44B
AUM Growth
+$573M
Cap. Flow
-$7.94M
Cap. Flow %
-0.55%
Top 10 Hldgs %
79.03%
Holding
50
New
2
Increased
4
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$8.82M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.28M
3
ASLN
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
+$7.68M
4
FULC icon
Fulcrum Therapeutics
FULC
+$4.93M
5
ZLAB icon
Zai Lab
ZLAB
+$2.99M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$27.3M
2
VERA icon
Vera Therapeutics
VERA
+$7.75M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$5.18M
4
MRUS
Merus
MRUS
+$1.48M
5
CMPX icon
Compass Therapeutics
CMPX
+$6.31K

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Materials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$615M 42.7%
5,900,000
– –
GTH
2
DELISTED
Genetron Holdings Limited ADS
GTH
$105M 7.26%
2,708,058
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$85.3M 5.92%
4,249,918
– –
HRMY icon
4
Harmony Biosciences
HRMY
$2.07B
$85.1M 5.9%
2,606,247
– –
TERN
5
DELISTED
Terns Pharmaceuticals
TERN
$78.8M 5.47%
6,657,992
– –
VRDN icon
6
Viridian Therapeutics
VRDN
$2.15B
$42.7M 2.96%
1,678,207
– –
GERN icon
7
Geron
GERN
$930M
$41.8M 2.9%
19,282,834
– –
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
$34.5M 2.39%
3,761,438
+1,007,343
+37% +$8.28M
TARS icon
9
Tarsus Pharmaceuticals
TARS
$2.57B
$28.4M 1.97%
2,262,200
– –
ATXS
10
DELISTED
Astria Therapeutics
ATXS
$22.4M 1.55%
1,681,199
– –
PCVX icon
11
Vaxcyte
PCVX
$7.88B
$21.7M 1.51%
579,508
– –
COGT icon
12
Cogent Biosciences
COGT
$6.95B
$21.5M 1.49%
1,994,941
– –
KDNY
13
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$20.2M 1.4%
872,151
– –
VTYX
14
DELISTED
Ventyx Biosciences
VTYX
$20.2M 1.4%
602,075
-701,219
-54% -$27.3M
VECT
15
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$19.9M 1.38%
2,333,300
– –
ALXO icon
16
ALX Oncology
ALXO
$268M
$19.1M 1.32%
4,220,048
– –
ALLK
17
DELISTED
Allakos
ALLK
$18.3M 1.27%
4,120,134
– –
ZLAB icon
18
Zai Lab
ZLAB
$2.1B
$13.9M 0.96%
416,640
+77,919
+23% +$2.99M
LEGN icon
19
Legend Biotech
LEGN
$3.68B
$11.8M 0.82%
244,375
– –
CMPX icon
20
Compass Therapeutics
CMPX
$367M
$11.6M 0.81%
3,556,023
-1,607
-0% -$6.31K
AMRS
21
DELISTED
Amyris Inc.
AMRS
$10.5M 0.73%
7,750,828
– –
ACLX
22
DELISTED
Arcellx
ACLX
$8.96M 0.62%
+290,713
New +$8.82M
TIL icon
23
Instil Bio
TIL
$49.4M
$8.25M 0.57%
624,339
– –
BLU
24
DELISTED
BELLUS Health Inc.
BLU
$7.32M 0.51%
1,017,152
– –
ACRS icon
25
Aclaris Therapeutics
ACRS
$744M
$7.27M 0.5%
898,631
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Vivo Capital held 50 positions worth $1.44B, up 66% from $869M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Vivo Capital's Q1 2023 filing shows 2 new, 4 increased, 3 reduced and 2 closed positions. Its largest new stake was Arcellx: 290,713 shares worth $8.96M. The largest sale was Ventyx Biosciences, an estimated $27.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q1 2023 buy was Arcellx: 290,713 shares worth $8.96M.
  • Vivo Capital added most to Avadel Pharmaceuticals in Q1 2023, an estimated $8.28M increase.
  • Vivo Capital's biggest Q1 2023 reduction was Ventyx Biosciences, cutting an estimated $27.3M.
  • Vivo Capital fully exited Vera Therapeutics in Q1 2023, selling an estimated $7.75M.
  • Vivo Capital's ten largest holdings make up 79% of its $1.44B portfolio in Q1 2023.
  • Vivo Capital opened 2 new positions and closed 2 in Q1 2023.
  • Vivo Capital's portfolio value rose 66% quarter-over-quarter to $1.44B.

Based on Vivo Capital's 13F filing for Q1 2023, filed 15 May 2023.